Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2010

01-07-2010 | Article

Hepatocyte nuclear factor (HNF)-4α-driven epigenetic silencing of the human PED gene

Authors: P. Ungaro, R. Teperino, P. Mirra, M. Longo, M. Ciccarelli, G. A. Raciti, C. Nigro, C. Miele, P. Formisano, F. Beguinot

Published in: Diabetologia | Issue 7/2010

Login to get access

Abstract

Aims/hypothesis

Overexpression of PED (also known as PEA15) determines insulin resistance and impaired insulin secretion and may contribute to progression toward type 2 diabetes. Recently, we found that the transcription factor hepatocyte nuclear factor (HNF)-4α binds to PED promoter and represses its transcription. However, the molecular details responsible for regulation of PED gene remain unclear.

Methods

Here we used gain and loss of function approaches to investigate the hypothesis that HNF-4α controls chromatin remodelling at the PED promoter in human cell lines.

Results

HNF-4α production and binding induce chromatin remodelling at the −250 to 50 region of PED, indicating that remodelling is limited to two nucleosomes located at the proximal promoter. Chromatin immunoprecipitation assays also revealed concomitant HNF-4α-induced deacetylation of histone H3 at Lys9 and Lys14, and increased dimethylation of histone H3 at Lys9. The latter was followed by reduction of histone H3 Lys4 dimethylation. HNF-4α was also shown to target the histone deacetylase complex associated with silencing mediator of retinoic acid and thyroid hormone receptor, both at the PED promoter, and at GRB14 and USP21 regulatory regions, leading to a reduction of mRNA levels. Moreover, HNF-4α silencing and PED overexpression were accompanied by a significant reduction of hepatic glycogen content.

Conclusions/interpretation

These results show that HNF-4α serves as a scaffold protein for histone deacetylase activities, thereby inhibiting liver expression of genes including PED. Dysregulation of these mechanisms may lead to upregulation of the PED gene in type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885CrossRefPubMed
2.
Saxena R, Voight B, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336CrossRefPubMed
3.
Prokopenko I, McCarthy M, Lindgren C (2008) Type 2 diabetes: new genes, new understanding. Trends Genet 24:613–621CrossRefPubMed
4.
Danziger N, Yokoyama M, Jay T, Cordier J, Glowinski J, Chneiweiss H (1995) Cellular expression, developmental regulation, and phylogenic conservation of PEA-15, the astrocytic major phosphoprotein and protein kinase C substrate. J Neurochem 64:1016–1025PubMedCrossRef
5.
Condorelli G, Vigliotta G, Iavarone C et al (1998) PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J 17:3858–3866CrossRefPubMed
6.
Condorelli G, Vigliotta G, Trencia A et al (2001) Protein kinase C (PKC)-alpha activation inhibits PKC-zeta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells. Diabetes 50:1244–1252CrossRefPubMed
7.
Valentino R, Lupoli GA, Raciti GA et al (2006) In healthy first-degree relatives of type 2 diabetics, ped/pea-15 gene is overexpressed and related to insulin resistance. Diabetologia 49:3058–3066CrossRefPubMed
8.
Perfetti A, Oriente F, Iovino S et al (2007) Phorbol esters induce intracellular accumulation of the anti-apoptotic protein ped/pea-15 by preventing ubiquitinylation and proteasomal degradation. J Biol Chem 282:8648–8657CrossRefPubMed
9.
Hayhurst G, Lee Y, Lambert G, Ward J, Gonzalez F (2001) Hepatocyte nuclear factor 4 alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 21:1393–1403CrossRefPubMed
10.
Pereira F, Tsai M, Tsai S (2000) COUP-TF orphan nuclear receptors in development and differentiation. Cell Mol Life Sci 57:1388–1398CrossRefPubMed
11.
Ungaro P, Teperino R, Mirra P et al (2008) Molecular cloning and characterization of the human PED/PEA-15 gene promoter reveal antagonistic regulation by hepatocyte nuclear factor 4 alpha and chicken ovalbumin upstream promoter transcription factor II. J Biol Chem 283:30970–30979CrossRefPubMed
12.
Li J, Ning G, Duncan SA (2000) Mammalian hepatocyte differentiation requires the transcription factor HNF-4a. Genes Dev 14:464–474PubMed
13.
Parviz F, Matullo C, Garrison W et al (2003) Hepatocyte nuclear factor 4 alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 34:292–296CrossRefPubMed
14.
Black MH, Fingerlin TE, Allayee H et al (2008) Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes 57:1048–1056CrossRefPubMed
15.
Menjivar M, Granados-Silvestre MA, Montùfar-Robles I et al (2008) High frequency of T130I mutation of HNF4A gene in Mexican patients with early-onset type 2 diabetes. Clin Genet 73:185–187CrossRefPubMed
16.
Johansson S, Raeder H, Eide SA et al (2007) Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate that variants in the hepatocyte nuclear factor 4 alpha (HNF4A) P2 region are associated with type 2 diabetes in Scandinavians. Diabetes 56:3112–3117CrossRefPubMed
17.
Rosenfeld MG, Lunyak VV, Glass CK (2006) Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20:1405–1428CrossRefPubMed
18.
Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nat Genet 403:41–45CrossRef
19.
Kouzarides T (2007) Chromatin modifications and their function. Cell Mol Life Sci 128:693–705
20.
Saha A, Wittmeyer J, Cairns BR (2006) Chromatin remodelling: the industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 7:437–447CrossRefPubMed
21.
Roth TY, Cuddapah S, Cui K, Zhao K (2006) The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci USA 103:15782–15787CrossRef
22.
Kurdistani SK, Tavazoie S, Grunstein M (2004) Mapping global histone acetylation patterns to gene expression. Cell 117:721–733CrossRefPubMed
23.
Schubeler D, MacAlpine DM, Scalzo D et al (2004) The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 18:1263–1271CrossRefPubMed
24.
Fischle W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15:172–183CrossRefPubMed
25.
Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL (2007) The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 27:5933–5948CrossRefPubMed
26.
Vigliotta G, Miele C, Santopietro S et al (2004) Overexpression of the ped/pea-15 gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action. Mol Cell Biol 24:5005–5015CrossRefPubMed
27.
Rao S, Procko E, Shannon MF (2001) Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J Immunol 167:4494–4503PubMed
28.
Hogan GJ, Lee C, Lieb JD (2006) Cell cycle-specified fluctuation of nucleosome occupancy at gene promoters. PLoS Genetics 2:1433–1450CrossRef
29.
Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305–312CrossRefPubMed
30.
Santos-Rosa H, Schneider R, Bannister AJ et al (2002) Active genes are tri-methylated at K4 of histone H3. Nature 419:407–411CrossRefPubMed
31.
Lachner M, O’Sullivan RJ, Jenuwein T (2003) An epigenetic road map for histone lysine methylation. J Cell Sci 116:2117–2124CrossRefPubMed
32.
Chen J, Kinyamu HK, Archer TK (2009) Changes in attitude, changes in latitude: nuclear receptors remodeling chromatin to regulate transcription. Mol Endocrinol 20:1–13CrossRef
33.
McKenna NJ, O’Malley BW (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465–474CrossRefPubMed
34.
Grignani F, de Matteis S, Nervi C et al (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815–818CrossRefPubMed
35.
Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R (2000) A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 14:1048–1057PubMed
36.
Gupta R, Vatamaniuk M, Lee C et al (2005) The MODY gene HNF4alpha regulates selected genes involved in insulin secretion. J Clin Invest 115:1006–1015PubMed
37.
Hohmeier H, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard C (2000) Isolation of INS-1 derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49:424–430CrossRefPubMed
38.
Ruse MDJ, Privalsky ML, Sladek FM (2002) Competitive cofactor recruitment by orphan receptor hepatocyte nuclear factor 4 alpha 1: modulation by the F domain. Mol Cell Biol 22:1626–1638CrossRefPubMed
39.
Odom DT, Zizlsperger N, Gordon DB et al (2004) Control of pancreas and liver gene expression by HNF transcription factors. Science 303:1378–1381CrossRefPubMed
40.
Sladek F, Zhong WM, Lai E, Darnell JE (1990) Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4:2353–2365CrossRefPubMed
41.
Wang JC, Stafford JM, Granner DK (1998) SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4. J Biol Chem 273:30847–30850CrossRefPubMed
42.
Yoshida E, Aratani S, Itou H et al (1997) Functional association between CBP and HNF-4 in trans-activation. Biochem Biophys Res Commun 241:664–669CrossRefPubMed
43.
Nofsinger RR, Li P, Hong SH et al (2008) SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. Proc Natl Acad Sci USA 105:20021–20026CrossRefPubMed
44.
Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet Supplement 33:245–254CrossRef
45.
Tremblay J, Hamet P (2008) Impact of genetic and epigenetic factors from early life to later disease. Metabolism 57:S27–S31CrossRefPubMed
46.
Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. Nat Rev Genet 8:253–262CrossRefPubMed
47.
Park JH, Stoffers DA, Nicholls RD, Simmons RA (2008) Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 118:2316–2324CrossRefPubMed
48.
Dabelea D, Mayer-Davis E, Lamichhane A et al (2008) Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case–Control Study. Diabetes Care 31:1422–1426CrossRefPubMed
49.
Gill-Randall R, Adams D, Ollerton R, Lewis M, Alcolado J (2004) Type 2 diabetes mellitus—genes or intrauterine environment? An embryo transfer paradigm in rats. Diabetologia 47:1354–1359CrossRefPubMed
50.
Dabelea D, Pettitt D (2001) Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J Pediatr Endocrinol Metab 14:1085–1091PubMed
51.
Diakoumopoulou E, Tentolouris N, Kirlaki E et al (2005) Plasma homocysteine levels in patients with type 2 diabetes in a Mediterranean population: relation with nutritional and other factors. Nutr Metab Cardiovasc Dis 15:109–117CrossRefPubMed
52.
Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H (1999) Heritability of type II (non insulin-dependent) diabetes mellitus and abnormal glucose tolerance—a population-based twin study. Diabetologia 42:139–145CrossRefPubMed
Metadata
Title
Hepatocyte nuclear factor (HNF)-4α-driven epigenetic silencing of the human PED gene
Authors
P. Ungaro
R. Teperino
P. Mirra
M. Longo
M. Ciccarelli
G. A. Raciti
C. Nigro
C. Miele
P. Formisano
F. Beguinot
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1732-x

Other articles of this Issue 7/2010

Diabetologia 7/2010 Go to the issue

Article

Direct evidence for susceptibility genes for type 2 diabetes on mouse chromosomes 11 and 14

Article

A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)γa as a pancreatic beta cell-specific biomarker

Article

Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study

Article

Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-γ (PPAR-γ)-deficient mice

Article

Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study

Article

TRIB3 R84 variant affects glucose homeostasis by altering the interplay between insulin sensitivity and secretion
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits